Literature DB >> 29872574

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1.

Lisa Derosa1,2,3,4, Bertrand Routy1,2,3,4,5,6, Guido Kroemer7,8,9,10,11,12,10,13, Laurence Zitvogel1,2,3,4,5,6,7,8,9,10,11,12,10,13,14.   

Abstract

Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy.

Entities:  

Keywords:  Biomarkers; Inflammation and cancer; Microbiota; NSCLC; New target; PD-1/PD-L1; RCC; immune checkpoint blockers

Year:  2018        PMID： 29872574      PMCID： PMC5980343          DOI： 10.1080/2162402X.2018.1434468

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Authors:  David P Carbone; Martin Reck; Luis Paz-Ares; Benjamin Creelan; Leora Horn; Martin Steins; Enriqueta Felip; Michel M van den Heuvel; Tudor-Eliade Ciuleanu; Firas Badin; Neal Ready; T Jeroen N Hiltermann; Suresh Nair; Rosalyn Juergens; Solange Peters; Elisa Minenza; John M Wrangle; Delvys Rodriguez-Abreu; Hossein Borghaei; George R Blumenschein; Liza C Villaruz; Libor Havel; Jana Krejci; Jesus Corral Jaime; Han Chang; William J Geese; Prabhu Bhagavatheeswaran; Allen C Chen; Mark A Socinski
Journal:  N Engl J Med       Date:  2017-06-22       Impact factor: 91.245

2.  The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

Authors:  Vyara Matson; Jessica Fessler; Riyue Bao; Tara Chongsuwat; Yuanyuan Zha; Maria-Luisa Alegre; Jason J Luke; Thomas F Gajewski
Journal:  Science       Date:  2018-01-05       Impact factor: 47.728

3.  Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Authors:  V Gopalakrishnan; C N Spencer; L Nezi; A Reuben; M C Andrews; T V Karpinets; P A Prieto; D Vicente; K Hoffman; S C Wei; A P Cogdill; L Zhao; C W Hudgens; D S Hutchinson; T Manzo; M Petaccia de Macedo; T Cotechini; T Kumar; W S Chen; S M Reddy; R Szczepaniak Sloane; J Galloway-Pena; H Jiang; P L Chen; E J Shpall; K Rezvani; A M Alousi; R F Chemaly; S Shelburne; L M Vence; P C Okhuysen; V B Jensen; A G Swennes; F McAllister; E Marcelo Riquelme Sanchez; Y Zhang; E Le Chatelier; L Zitvogel; N Pons; J L Austin-Breneman; L E Haydu; E M Burton; J M Gardner; E Sirmans; J Hu; A J Lazar; T Tsujikawa; A Diab; H Tawbi; I C Glitza; W J Hwu; S P Patel; S E Woodman; R N Amaria; M A Davies; J E Gershenwald; P Hwu; J E Lee; J Zhang; L M Coussens; Z A Cooper; P A Futreal; C R Daniel; N J Ajami; J F Petrosino; M T Tetzlaff; P Sharma; J P Allison; R R Jenq; J A Wargo
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

4.  Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Authors:  Bertrand Routy; Emmanuelle Le Chatelier; Lisa Derosa; Connie P M Duong; Maryam Tidjani Alou; Romain Daillère; Aurélie Fluckiger; Meriem Messaoudene; Conrad Rauber; Maria P Roberti; Marine Fidelle; Caroline Flament; Vichnou Poirier-Colame; Paule Opolon; Christophe Klein; Kristina Iribarren; Laura Mondragón; Nicolas Jacquelot; Bo Qu; Gladys Ferrere; Céline Clémenson; Laura Mezquita; Jordi Remon Masip; Charles Naltet; Solenn Brosseau; Coureche Kaderbhai; Corentin Richard; Hira Rizvi; Florence Levenez; Nathalie Galleron; Benoit Quinquis; Nicolas Pons; Bernhard Ryffel; Véronique Minard-Colin; Patrick Gonin; Jean-Charles Soria; Eric Deutsch; Yohann Loriot; François Ghiringhelli; Gérard Zalcman; François Goldwasser; Bernard Escudier; Matthew D Hellmann; Alexander Eggermont; Didier Raoult; Laurence Albiges; Guido Kroemer; Laurence Zitvogel
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

5.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

6.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Authors:  Ayelet Sivan; Leticia Corrales; Nathaniel Hubert; Jason B Williams; Keston Aquino-Michaels; Zachary M Earley; Franco W Benyamin; Yuk Man Lei; Bana Jabri; Maria-Luisa Alegre; Eugene B Chang; Thomas F Gajewski
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

9.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors:  Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728
  9 in total
  19 in total

Review 1.  A review of cancer immunotherapy: from the past, to the present, to the future.

Authors:  K Esfahani; L Roudaia; N Buhlaiga; S V Del Rincon; N Papneja; W H Miller
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

2.  Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.

Authors:  Nadina Tinsley; Cong Zhou; Grace Tan; Samuel Rack; Paul Lorigan; Fiona Blackhall; Matthew Krebs; Louise Carter; Fiona Thistlethwaite; Donna Graham; Natalie Cook
Journal:  Oncologist       Date:  2019-07-10

3.  Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer.

Authors:  Jarred P Reed; Suzanne Devkota; Robert A Figlin
Journal:  Ann Transl Med       Date:  2019-12

4.  Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.

Authors:  Zhitao Dong; Boyi Liao; Weifeng Shen; Chengjun Sui; Jiamei Yang
Journal:  Dig Dis Sci       Date:  2019-08-13       Impact factor: 3.199

5.  Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors.

Authors:  Marion Tonneau; Alexis Nolin-Lapalme; Suzanne Kazandjian; Edouard Auclin; Justin Panasci; Myriam Benlaifaoui; Mayra Ponce; Afnan Al-Saleh; Wiam Belkaid; Sabrine Naimi; Catalin Mihalcioiu; Ian Watson; Mickael Bouin; Wilson Miller; Marie Hudson; Matthew K Wong; Rossanna C Pezo; Simon Turcotte; Karl Bélanger; Rahima Jamal; Paul Oster; Dominique Velin; Corentin Richard; Meriem Messaoudene; Arielle Elkrief; Bertrand Routy
Journal:  Oncoimmunology       Date:  2022-07-07       Impact factor: 7.723

6.  Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer.

Authors:  Anna Grenda; Ewelina Iwan; Izabela Chmielewska; Paweł Krawczyk; Aleksandra Giza; Arkadiusz Bomba; Małgorzata Frąk; Anna Rolska; Michał Szczyrek; Robert Kieszko; Tomasz Kucharczyk; Bożena Jarosz; Dariusz Wasyl; Janusz Milanowski
Journal:  AMB Express       Date:  2022-07-06       Impact factor: 4.126

7.  Clinical Significance of Fusobacterium nucleatum and Microsatellite Instability in Evaluating Colorectal Cancer Prognosis.

Authors:  Qiaoxin Zhang; Yong Xia; Yanxuan Xie; Xiaoyang Jiao; Mi Zeng; Zhiqiang Fan; Xin Li; Yumeng Yuan
Journal:  Cancer Manag Res       Date:  2022-10-18       Impact factor: 3.602

8.  Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer.

Authors:  N Tinsley; C Zhou; S Nahm; S Rack; G C L Tan; P Lorigan; F Blackhall; N Cook
Journal:  ESMO Open       Date:  2022-04-27

Review 9.  Intestinal microbiota: a new force in cancer immunotherapy.

Authors:  Zhujiang Dai; Jingqiu Zhang; Qi Wu; Huiwen Fang; Chunfeng Shi; Zhen Li; Chaobiao Lin; Dong Tang; Daorong Wang
Journal:  Cell Commun Signal       Date:  2020-06-10       Impact factor: 5.712

Review 10.  Trial watch: Peptide-based vaccines in anticancer therapy.

Authors:  Lucillia Bezu; Oliver Kepp; Giulia Cerrato; Jonathan Pol; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.